Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

PDS Biotechnology Corporation (PDSB) USD0.00033

Sell:$2.67 Buy:$2.77 Change: $0.15 (5.14%)
NASDAQ:0.13%
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
Sell:$2.67
Buy:$2.77
Change: $0.15 (5.14%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
Sell:$2.67
Buy:$2.77
Change: $0.15 (5.14%)
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Contact details

Address:
303A College Rd E
PRINCETON
08540-6608
United States
Telephone:
+ ()
Website:
www.pdsbiotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PDSB
ISIN:
US70465T1079
Market cap:
$16.87 million
Shares in issue:
5.28 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Frank Bedu-Addo
    President, Chief Executive Officer, Director
  • Andrew Saik
    Chief Financial Officer, Director
  • Gregory Conn
    Chief Scientific Officer
  • Lauren Wood
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.